Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC13 | PNEUMO (PREVNAR13) | PFIZER\WYETH | 1 | — | — |
| PNC13 | PNEUMO (PREVNAR13) | PFIZER\WYETH | 2 | — | — |
| PPV | PNEUMO (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
| PPV | PNEUMO (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
other/ other sterile site (Pneumococcal infection); This spontaneous report has been downloaded from regulatory authority and referred to a child female patient of unknown exact age (age group 5-9). The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On an unknown dates, the patient was vaccinated with first and second dose of Prevenar 13 (Pneumococcal vaccine conj 13v (CRM197)). On an unknown date, the patient was vaccinated with unspecified pneumococcal vaccine, captured as pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) solution for injection and 15-Valent Pneumococcal Conjugate Vaccine (CRM197) (VAXNEUVANCE) suspension for injection, 2 times in total (vague information) (Batch/Lot Number was not provided), administered as prophylaxis. On an unspecified date in 2024, the patient experienced Pneumococcal infection (reported as other/ other sterile site); serotype showed 19F. The Outcome of Pneumococcal infection was not provided. The action taken with the suspect vaccines was not applicable with Not Applicable dechallenge and rechallenge results. The causality for the event Pneumococcal infection to the suspect vaccines was not reported. Upon internal review, the event Pneumococcal infection was determined to be Medically Significant.
Test Date: 2024; Test Name: Serotype; Result Unstructured Data: 19F